Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Studies from Meharry Medical College, Medical College further understanding of breast cancer
February 12th, 2009
According to recent research published in the journal Breast Cancer Research and Treatment, "2-Methoxyestradiol (2ME), a natural derivative of estradiol, is currently evaluated in clinical trials for breast cancer. The current study aims to evaluate the modulatory effects of 2ME on regulation of multidrug resistance (MDR) in doxorubicin (Dox) resistant breast cancer cells (MCF-7/Dox) and its underlying mechanisms." "The chemosensitizing effect of 2ME on Dox cytotoxicity is tested by MTT assay. RT2 Profiler PCR Array was used to identify differentially expressed genes in Dox and/or 2ME treatment groups, based on significance of results 4 genes were selected: MDR1,...
Source: Women's Health Weekly (2009-02-12)
|
